Banking on Opdivo/Yervoy combo, Bristol-Myers Squibb teases out Checkmate-227 again at ESMO
BARCELONA — Some might consider the dust settled on Merck and Bristol-Myers Squibb’s rivalry over frontline lung cancer, but Bristol-Myers is not giving up without another pitch for its Opdivo/Yervoy combo.
In another look at the much reported Checkmate-227 trial, investigators broke down the median OS for the combo versus chemo alone — a small win in Part 1 that was overshadowed by a flop in part 2. While Merck’s dominant regimen involves pairing Keytruda with chemotherapy, Bristol-Myers wonders if an I/O-I/O combo free of chemo would make a compelling case.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.